CLN Stock Analysis: Clariant | SW
Specialty Chemicals | SW, Switzerland | Market Cap: 2.442m CHF | 12M Return: -11% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.79M
EPS Trend: -69.5%
Qual. Beats: -1
Rev. Trend: -91.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Clariant AG (CLN) is a Switzerland-based specialty chemicals company founded in 1886 and headquartered in Muttenz. Operating as a mid-cap stock in the Materials sector, the company develops, manufactures, and distributes chemical products across Switzerland, Europe, the Middle East, Africa, the United States, and Asia Pacific.
The business is organized into three segments: Care Chemicals, which serves personal care, home care, crop solutions, and industrial applications; Catalysts, focused on propylene, ethylene, syngas, and fuel technologies; and Adsorbents & Additives, which supplies solutions for coatings, adhesives, polymers, automotive, electronics, and construction markets. This diversified segment structure reflects the broader specialty chemicals industrys strategy of tailoring high-margin, application-specific products across multiple end markets rather than competing in commodity chemicals.
Clariants broad geographic footprint and presence in both consumer-driven segments (personal and home care) and industrial segments (catalysts, mining, automotive) illustrate the cross-cyclical nature of the specialty chemicals business model, where revenue is tied to diverse end-market demand drivers.
- Catalysts orders track global ethylene and propylene capex
- Care Chemicals pricing offsets crop solutions volume softness
- Portfolio divestitures and cost savings accelerate capital returns
| Net Income: -75.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.00 > 1.0 |
| NWC/Revenue: 22.17% < 20% (prev 16.31%; Δ 5.87% < -1%) |
| CFO/TA 0.06 > 3% & CFO 379.0m > Net Income -75.0m |
| Net Debt (1.79b) to EBITDA (558.0m): 3.21 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (326.8m) vs 12m ago -1.08% < -2% |
| Gross Margin: 31.19% > 18% (prev 31.05%; Δ 0.14% > 0.5%) |
| Asset Turnover: 64.52% > 50% (prev 66.28%; Δ -1.76% > 0%) |
| Interest Coverage Ratio: 0.92 > 6 (EBIT TTM 306.0m / Interest Expense TTM 334.0m) |
| A: 0.15 (Total Current Assets 2.23b - Total Current Liabilities 1.36b) / Total Assets 5.87b |
| B: 0.49 (Retained Earnings 2.91b / Total Assets 5.87b) |
| C: 0.05 (EBIT TTM 306.0m / Avg Total Assets 6.07b) |
| D: 0.55 (Book Value of Equity 2.02b / Total Liabilities 3.69b) |
| Altman-Z'' = 3.50 = A |
| DSRI: 0.82 (Receivables 691.0m/891.0m, Revenue 3.92b/4.15b) |
| GMI: 1.00 (GM 31.05% / 31.19%) |
| AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 0.94 (Revenue 3.92b / 4.15b) |
| TATA: -0.08 (NI -75.0m - CFO 379.0m) / TA 5.87b) |
| Beneish M = -3.27 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at CHF 7.42 with a total of 723,535 shares traded. Over the past week, the price has changed by +2.91%, over one month by +3.71%, over three months by -1.77% and over the past year by -11.04%.
Current recommended Stop Loss: 7.10 (which is 4.3% or 1.5 ATR below the current price).
Clariant has no consensus analysts rating.
P/E Forward = 11.7233
P/S = 0.6237
P/B = 1.1813
P/EG = 0.9016
Revenue TTM = 3.92b CHF
EBIT TTM = 306.0m CHF
EBITDA TTM = 558.0m CHF
Long Term Debt = 1.53b CHF (from longTermDebt, last quarter)
Short Term Debt = 369.0m CHF (from shortTermDebt, last quarter)
Debt = 2.20b CHF (from shortLongTermDebtTotal, last quarter) + Leases 172.0m
Net Debt = 1.79b CHF (calculated: Debt 2.20b - CCE 411.0m)
Enterprise Value = 4.23b CHF (2.44b + Debt 2.20b - CCE 411.0m)
Interest Coverage Ratio = 0.92 (Ebit TTM 306.0m / Interest Expense TTM 334.0m)
EV/FCF = 18.09x (Enterprise Value 4.23b / FCF TTM 234.0m)
FCF Yield = 5.53% (FCF TTM 234.0m / Enterprise Value 4.23b)
FCF Margin = 5.98% (FCF TTM 234.0m / Revenue TTM 3.92b)
Net Margin = -1.92% (Net Income TTM -75.0m / Revenue TTM 3.92b)
Gross Margin = 31.19% ((Revenue TTM 3.92b - Cost of Revenue TTM 2.69b) / Revenue TTM)
Gross Margin QoQ = 30.25% (prev 32.10%)
Tobins Q-Ratio = 0.72 (Enterprise Value 4.23b / Total Assets 5.87b)
Interest Expense / Debt = 15.16% (Interest Expense 334.0m / Debt 2.20b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 229.5m (EBIT 306.0m * (1 - 25.00%))
Current Ratio = 1.64 (Total Current Assets 2.23b / Total Current Liabilities 1.36b)
Debt / Equity = 1.09 (Debt 2.20b / totalStockholderEquity, last quarter 2.02b)
Debt / EBITDA = 3.21 (Net Debt 1.79b / EBITDA 558.0m)
Debt / FCF = 7.66 (Net Debt 1.79b / FCF TTM 234.0m)
Total Stockholder Equity = 2.11b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.24% (Net Income -75.0m / Total Assets 5.87b)
RoE = -3.55% (Net Income TTM -75.0m / Total Stockholder Equity 2.11b)
RoCE = 8.40% (EBIT 306.0m / Capital Employed (Equity 2.11b + L.T.Debt 1.53b))
RoIC = 4.90% (NOPAT 229.5m / Invested Capital 4.68b)
WACC = 9.79% (E(2.44b)/V(4.64b) * Re(8.36%) + D(2.20b)/V(4.64b) * Rd(15.16%) * (1-Tc(0.25)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -21.51 | Cagr: -0.32%
[DCF] Terminal Value 73.46% ; FCFF base≈215.2m ; Y1≈246.7m ; Y5≈363.1m
[DCF] Fair Price = 7.80 (EV 4.36b - Net Debt 1.79b = Equity 2.57b / Shares 328.9m; r=9.79% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -69.52 | EPS CAGR: -50.81% | SUE: -4.0 | # QB: -1
Revenue Correlation: -91.40 | Revenue CAGR: -7.52% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.24 | Chg30d=+3.95% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.68 | Chg30d=-2.22% | Revisions=-29% | GrowthEPS=+1159.2% | GrowthRev=-3.1%
EPS next Year (2027-12-31): EPS=0.81 | Chg30d=-2.78% | Revisions=-50% | GrowthEPS=+18.4% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -50% (up=1, down=6)